RenovaCare (OTCMKTS:RCAR) & Bioventus (NYSE:BVS) Head to Head Review

Bioventus (NYSE:BVS) and RenovaCare (OTCMKTS:RCAR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Bioventus and RenovaCare, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0	1	2	0	2.67
RenovaCare	0	0	0	0	0.00

Bioventus currently has a consensus target price of $14.33, suggesting a potential upside of 111.09%. Given Bioventus’ stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than RenovaCare.

Valuation & Earnings

This table compares Bioventus and RenovaCare”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$567.70 million	0.98	-$156.23 million	($0.48)	-14.15
RenovaCare	N/A	N/A	N/A	N/A	N/A

RenovaCare has lower revenue, but higher earnings than Bioventus.

Insider and Institutional Ownership

62.9% of Bioventus shares are held by institutional investors. 32.9% of Bioventus shares are held by insiders. Comparatively, 0.9% of RenovaCare shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Bioventus has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, RenovaCare has a beta of -99.34, indicating that its stock price is 10,034% less volatile than the S&P 500.

Profitability

This table compares Bioventus and RenovaCare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioventus	-7.11%	15.61%	4.01%
RenovaCare	N/A	N/A	N/A

Summary

Bioventus beats RenovaCare on 9 of the 10 factors compared between the two stocks.

About Bioventus

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

About RenovaCare

RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.